Stock comparison
ResMed
Travere Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
TVTX
Travere Therapeutics
Market cap
$3.99B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | TVTX | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 30F | RMD |
| Benjamin Graham | 67B | 55C | RMD |
| Philip Fisher | 67B | 44D | RMD |
| Peter Lynch | 50C | 73B | TVTX |
| Joel Greenblatt | 39D | 0F | RMD |
| Charlie Munger | 61C | 35D | RMD |
| Terry Smith | 65B | 31F | RMD |
Side-by-side metrics
| Metric | RMD | TVTX |
|---|---|---|
| Market cap | $29.57B | $3.99B |
| P/E (TTM) | 19.6x | - |
| EV/EBIT | 17.1x | - |
| ROIC (TTM) | 19.63% | -13.09% |
| Gross margin | 61.69% | 93.95% |
| Net margin | 27.44% | -4.0% |
| Revenue CAGR 5y | 12.64% | 38.9% |
| EPS CAGR 5y | 30.73% | - |
| Debt / Equity | 0.1x | 3.3x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- ROIC (TTM)19.63%vs -13.09%+167%
- Net margin27.44%vs -4.0%+115%
- Dividend yield1.14%vs 0.0%+100%
- Debt / Equity0.1xvs 3.3x+96%
TVTX leads on
- EV/EBIT-vs 17.1x+125%
- P/E (TTM)-vs 19.6x+111%
- Revenue CAGR 5y38.9%vs 12.64%+68%
- Gross margin93.95%vs 61.69%+34%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.